Haemonetics
207 hedge funds and large institutions have $2.46B invested in Haemonetics in 2017 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 77 increasing their positions, 72 reducing their positions, and 17 closing their positions.
76% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 17
12% more capital invested
Capital invested by funds: $2.19B → $2.46B (+$268M)
5% more funds holding
Funds holding: 197 → 207 (+10)
7% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 72
1.52% less ownership
Funds ownership: 105.66% → 104.14% (-1.5%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$15.8M |
| 2 |
NC
Nitorum Capital
New York
|
+$10.4M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$8.34M |
| 4 |
BlackRock
New York
|
+$7.9M |
| 5 |
Neuberger Berman Group
New York
|
+$7.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCIM
Black Creek Investment Management
Toronto,
Ontario, Canada
|
-$32.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$26M |
| 3 |
HM
HealthCor Management
New York
|
-$16.7M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$16.2M |
| 5 |
Morgan Stanley
New York
|
-$9.17M |
HAE Hedge Fund Activity: Q3 2017 in Review
207 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q3 2017, worth a combined $2.46B — up 12% from $2.19B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new HAE positions and 17 closed out — a net gain of 13 holders — while 77 added to existing stakes and 72 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $15.8M. The largest seller was Black Creek Investment Management, cutting an estimated $32.6M.
- 207 institutional investors held Haemonetics (HAE) as of Q3 2017, up from 197 in Q2 2017.
- Funds reported $2.46B of Haemonetics stock for Q3 2017, up 12% quarter-over-quarter.
- 30 funds opened new Haemonetics positions in Q3 2017 and 17 closed out, a net change of +13 holders.
- The largest Haemonetics buyer in Q3 2017 was Victory Capital Management, an estimated $15.8M added.
- The largest Haemonetics seller in Q3 2017 was Black Creek Investment Management, an estimated $32.6M sold.
Based on aggregated 13F filings for Q3 2017.